Differential stimulatory effects of cannabinoids on VIP release and NO synthase activity in synaptosomal fractions from rat ileum

Neuropeptides

Volumn 42, Issue 5-6, 2008, Pages 623-632

  Kurjak, M ^a   Hamel, A M ^b   Allescher, H D ^c   Schusdziarra, V ^d   Storr, M ^e  

^a Endooffice Friedenspromenade 40   (Germany)

^b Department of Psychiatry   (Germany)

^c Klinikum Garmisch Partenkirchen   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CB1 CB2 receptor; Enteric neurons; NANC relaxation; TRPV1 receptor

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ARGININE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RIMONABANT; TRITIUM; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME SYNTHESIS; ILEUM; INTESTINE INNERVATION; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOIMMUNOASSAY; RAT; SYNAPTOSOME;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; CANNABINOIDS; CAPSAICIN; HUMANS; ILEUM; MALE; MORPHOLINES; NAPHTHALENES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYUNSATURATED ALKAMIDES; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; SYNAPTOSOMES; VASOACTIVE INTESTINAL PEPTIDE;

RATTUS;

EID: 56349108450     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2008.08.003     Document Type: Article

References (57)

1. Adami M., Frati P., Bertini S., Kulkarni-Narla A., Brown D.R., De Caro G., Coruzzi G., and Soldani G. Gastic antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Brit. J. Pharmacol. 135 (2002) 1598-1606
2. Ball A.J., Moerschbaecher J.M., and Hornby P.J. Delta 9-tetrahydrocannabinol effects on gastric motility are mediated by a capsaicin-sensitive vagal pathway. Digestion 63 (2001) 269
3. Boeckxstaens G.E., Pelckmans P.A., Ruytjens I.F., Bult H., De Man J.G., Herman A.G., and Van Maercke Y.M. Bioassay of nitric oxide released upon stimulation of non-adrenergic non-chiolinergic nerves in the canine ileocolonic junction. Brit. J. Pharmacol. 103 (1991) 1085-1091
4. Breivogel C.S., Griffin G., Di Marzo V., and Martin B. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
5. Bradford M. A rapid and sensitive method for the quantification of microgramquatities of protein utilizing the principle of portein dye binding. Anal. Biochem. 72 (1976) 248-254
6. Bredt D.S., and Snyder S.H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Sci. 86 (1989) 9030-9033
7. Calignano A., La Rana G., Makryannis A., Lin S.Y., Beltramo L., and Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol. 340 (1997) R7-R8
8. Coutts A.A., and Pertwee R.G. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Brit. J. Pharmacol. 121 (1997) 1557-1566
9. Coutts A.A., Irving A.J., Mackie K., Pertwee R.G., and Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. 448 (2002) 410-422
10. Daniel E.E., Haugh C., Woskowska Z., Cipris S., Jury J., and Fox-Threlkeld J.E.T. Role of nitric oxide-related inhibition in intestinal function: relation to vasoactive intestinal polypeptide. Am. J. Physiol. 266 (1994) G31-G39
11. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., and Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of the anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483 (2000) 52-56
12. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Brit. J. Pharmacol. 141 (2004) 765-774
13. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
14. Duncan M., Mouihate A., Mackie K., Keenan C.M., Buckley N.E., Davison J.S., Patel K.D., Pittman Q.J., and Sharkey K.A. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysccharide-treated rats. Am. J. Physiol., Gastrointest. Liver Physiol. 295 1 (2008) G78-G87
15. Felder C.H.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., and Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Nat. Acad. Sci. 90 (1993) 7656-7660
16. Ghasemi M., Sadeghipour H., Mani A.R., Tavakoli S., Hajrasouliha A.R., Ebrahimi F., and Dehpour A.R. Effect of anandamide on nonadrenergic noncholinergic-mediated relaxations of rat corpus cavernosum. Eur. J. Pharmcol. 544 (2006) 138-145
17. Giuffrida A., Beltramo M., and Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. Pharmacol. Exp. Ther. 298 1 (2001) 7-14
18. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., and Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57 (2000) 1045-1050
19. Griffin G., Fernando S.R., Ross R.A., McKay N.G., Ashford M.L.J., Shire D., Huffman J.W., Yu S., Lainton J.A.H., and Pertwee R.G. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 339 (1997) 53-61
20. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
21. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mecoulam R., and Fride E. HU-308 a specific agonist for CB2, a peripheral cannabinoid receptor. PNAS 96 (1999) 14228-14233
22. Heinemann A., Shahbazian A., and Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 38 (1999) 289-1297
23. Hirsch D.P., Holloway R.H., Tytgat G.N., and Boeckxstaens G.E. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 115 (1998) 1374-1380
24. Hornby P.J., and Prouty S.M. Involvement of cannabinoid receptors in gut motility and visceral perception. Brit. J. Pharmacol. 141 (2004) 1335-1345
25. Izzo A.A. The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol. 1 (2001) 597-603
26. Izzo A.A., Mascolo N., Borrelli F., and Capasso F. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Brit. J. Pharmacol. 124 (1998) 363-1368
27. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. PNAS 96 (1999) 14136-14141
28. Kojima S., Sugiura T., Waku K., and Kamikawa Y. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of lingitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur. J. Pharmacol. 444 (2002) 203-207
29. Krowicki Z.K., Moerschbaecher J.M., Winsauer P.J., Digavalli S.V., and Hornby P.J. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur. J. Pharmacol. 371 (1999) 187-196
30. Kurjak M., Allescher H.D., Schusdziarra V., and Classen M. Release of bombesin-like immunoreactivity from synaptosomal membranes isolated from the rat ileum. Eur. J. Pharmacol. 257 1-2 (1994) 169-179
31. Kurjak M., Koppitz P., Schusdziarra V., and Allescher H.D. Evidence for a feedback inhibition of NO synthesis in enteric synaptosomes via a nitrosothiol intermediate. Am. J. Physiol. 277 (1999) G875-G884
32. Kurjak M., Fritsch R., Saur D., Schusdziarra V., and Allescher H.D. Functional coupling between nitric oxide synthesis and VIP release within enteric nerve terminals of the rat: involvement of protein kinase G and phosphodiesterase 5. J. Physiol. 534 (2001) 827-836
33. Landi M., Croci T., Rinaldi-Carmona M., Maffrand J.P., Le Fur G., and Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB1 receptors. Eur. J. Pharmacol. 450 (2002) 77-83
34. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., and Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. PNAS 105 7 (2008) 2699-2704
35. Lehmann A., Blackshaw L.A., Branden L., Carlsson A., Jensen J., Nygren E., and Smid S.D. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123 (2002) 1129-1134
36. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., D'argenio G., Scaglione G., Bifulco M., Sorrentini I., and Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125 (2003) 677-687
37. Manara L., Croci T., Guagnini F., Rinaldi-Carmona M., Maffrand J.P., Le Fur G., Mukenge S., and Ferla G. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig. Liver Dis. 34 (2002) 262-296
38. Mancinelli R., Fabrizi A., Del Monaco S., Azzena G.B., Varigiu R., Colongo G.C., and Gessa G.L. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci. 69 (2001) 101-111
39. Mascolo N., Izzo A.A., Ligresti A., Costagliola A., Pinto L., Cascio M.G., Maffia P., Cecio A., Capasso F., and Di Marzo V. The endocannabinoid system and the molecular basis of paralytic ileus in mice. Faseb J. 16 (2002) 1973-1975
40. Mathison R., Ho W., Pittman Q.J., Davison J.S., and Sharkey K.A. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Brit. J. Pharmacol. 142 8 (2004) 1247-1254
41. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
42. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., and Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
43. Mitchell S.J., and Bloom S.R. Measurement of fasting and postprandial VIP in man. Gut 19 (1978) 1043-1048
44. Mule F., Amato A., Baldassano S., and Serio R. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol. Res. 56 (2007) 185-192
45. Nieri P., Martinotti E., Testai L., Martinelli C., and Breschi M.C. Effects of cannabinoids on nonadrenergic noncholinergic-mediated relaxation in guinea-pig trachea. Eur. J. Pharmacol. 475 (2003) 115-118
46. Pertwee R.G. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurons and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci. 65 (1999) 597-605
47. Pertwee R.G. Cannabinoids and the gastrointestinal tract. Gut 48 6 (2001) 859-867
48. Pinto L., Izzo A.A., Cascio M.G., Bisogno T., Hospodar-Scott K., Brown D.R., Mascolo N., Di Marzo V., and Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123 (2002) 227-234
49. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., and Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
50. Stefano G.B., Esch T., Cadet P., Zhu W., Mantione K., and Benson H. Endocannabinoids as autoregulatory signaling molecules: coupling to nitric oxide and a possible association with the relaxation response. Med. Sci. Monit. 9 4 (2003) 63-75
51. Storr M., Gaffal E., Saur D., Schusdziarra V., and Allescher H.D. Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharmacol. 80 (2002) 67-76
52. Storr M., Sibaev A., Marsicano G., Lutz B., Schusdziarra V., Timmermans J.P., and Allescher H.D. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am. J. Physiol., Gastrointest. Liver Physiol. 286 (2004) 110-117
53. Todorov S., Pozzoli C., Zamfirova R., and Poli E. Prejunctional modulation of non-adrenergic non-cholinergic (NANC) inhibitory responses in the isolated guinea-pig gastric fundus. Neurogastroenterol. Motil. 15 (2003) 299-306
54. Varga K., Lake K.D., and Huangfu D. Mechanism of the hypotensive action of anandamide in anesthesized rats. Hypertension 28 (1996) 682-686
55. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682
56. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M., and Ward S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129 2 (2005) 437-453
57. Wright K.L., Duncan M., and Sharkey K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Brit. J. Pharmacol. 153 (2008) 263-270